GlassScriptPhysician profile
Clayton Adams
NPI 1699069104
$21,937.85
in general payments reported to CMS, 2019-2025
32 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 82% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $1,809 · 2021: $3,449 · 2022: $5,895 · 2023: $3,036 · 2024: $4,464 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,364 · Travel and Lodging: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,364.28 |
| Travel and Lodging | $623.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,475.39 | 2019-2025 | Octrode, Proclaim, Eterna |
| Boston Scientific Corporation | $1,793.54 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Infinion 16 |
| Biodelivery Sciences International, INC. | $1,058.54 | 2020-2021 | |
| Nalu Medical, INC. | $351.87 | 2021-2024 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $268.82 | 2019-2024 | Belbuca, Xtampza |
| Abbvie INC. | $247.09 | 2022-2024 | Qulipta, Ubrelvy, Botox |
| Nevro Corp. | $188.62 | 2019 | |
| Amgen INC. | $162.74 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.44 | 2022 | |
| Spr Therapeutics, INC | $137.79 | 2025 | Sprint Pns System |
| Medtronic USA, INC. | $126.53 | 2020 | |
| Allergan, INC. | $117.05 | 2020 | |
| Novartis Pharmaceuticals Corporation | $100.41 | 2019-2021 | |
| Medtronic, INC. | $92.44 | 2021-2023 | Synchromedii |
| Arbor Pharmaceuticals, INC. | $77.37 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.74 | 2021-2023 | Relistor |
| Pfizer INC. | $69.59 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $59.26 | 2019-2021 | |
| Grt US Holding, INC. | $46.48 | 2022 | |
| Saluda Medical Americas, INC. | $46.11 | 2025 | Evoke |
| Biohaven Pharmaceuticals, INC. | $45.82 | 2021 | |
| Scilex Pharmaceuticals INC. | $44.09 | 2019-2021 | |
| Redhill Biopharma INC. | $32.03 | 2021-2022 | |
| Argenx US, INC. | $29.51 | 2023 | Vyvgart |
| Forte Bio-Pharma LLC | $25.08 | 2019 | |
| Upsher-Smith Laboratories LLC | $22.22 | 2022 | |
| Assertio Therapeutics, INC. | $22.09 | 2020 | |
| Azurity Pharmaceuticals, INC. | $20.01 | 2023 | Horizant |
| Ibsa Pharma INC. | $19.93 | 2022 | |
| Eisai INC. | $17.07 | 2021 | |
| Mdd US Operations, LLC | $14.74 | 2019 | |
| Daiichi Sankyo INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.